A Multi-center, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of JYP0015 in Advanced Solid Tumors With RAS Mutation
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
Evaluate the safety and antitumor activity of JYP0015 in adults with specific RAS mutant advanced solid tumors.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Histologically or pathologically confirmed solid tumors with RAS mutation via molecular tests.
• Patients with RAS mutation who have disease progression or intolerance after adequate standard treatment
• Eastern Cooperative Oncology Group (ECOG) performance status in 0 or 1
• Adequate organ function
Locations
Other Locations
China
Beijing Cancer Hospital
RECRUITING
Beijing
Contact Information
Primary
Ling Shen, M.D.
linshenpku@163.com
01088121122
Backup
Xiao
Time Frame
Start Date: 2025-03-31
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 210
Treatments
Experimental: JYP0015 in RAS-Mutant Solid Tumors
This arm includes participants with histologically or pathologically confirmed advanced solid tumors harboring RAS mutations, identified via molecular testing. RAS mutations are defined as nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, 61, 117, or 146 (e.g., G12, G13, Q61, K117, or A146). Participants will receive JYP0015 as an oral tablet.
Related Therapeutic Areas
Sponsors
Leads: Guangzhou JOYO Pharma Co., Ltd